Jasper Therapeutics, Inc. (JSPR)
Price:
2.43 USD
( + 0.03 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
NEWS
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-10-07 17:07:00NEW YORK , Oct. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
2025-10-07 16:00:00LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). IF YOU SUFFERED A LOSS ON YOUR JASPER INVESTMENTS, CLICK HERE BEFORE NOVEMBER 18, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
globenewswire.com
2025-10-07 15:00:00NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
prnewswire.com
2025-10-07 08:04:00LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Robbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPR
prnewswire.com
2025-10-06 19:10:00SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma.
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
globenewswire.com
2025-10-06 12:00:00NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers.
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
globenewswire.com
2025-10-05 23:28:00Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
globenewswire.com
2025-10-05 13:59:00NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors
globenewswire.com
2025-10-03 14:22:00LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Jasper Therapeutics, Inc., (“Jasper” or the "Company") (NASDAQ: JSPR) investors of a class action on behalf of investors that bought securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). Jasper investors have until November 18, 2025 to file a lead plaintiff motion.
DEADLINE ALERT for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
globenewswire.com
2025-10-03 13:14:00BENSALEM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
prnewswire.com
2025-10-03 11:25:00Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
prnewswire.com
2025-10-03 10:00:00NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
2025-10-02 17:15:00LOS ANGELES , Oct. 2, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR)have opportunity to lead the securities fraud class action lawsuit.
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-10-02 14:47:00NEW YORK , Oct. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
globenewswire.com
2025-10-01 14:55:00NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
2025-10-01 12:00:00BENSALEM, Pa. , Oct. 1, 2025 /PRNewswire/ -- The Law Offices of Howard G.
No data to display
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-10-07 17:07:00NEW YORK , Oct. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
2025-10-07 16:00:00LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). IF YOU SUFFERED A LOSS ON YOUR JASPER INVESTMENTS, CLICK HERE BEFORE NOVEMBER 18, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
globenewswire.com
2025-10-07 15:00:00NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
prnewswire.com
2025-10-07 08:04:00LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Robbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPR
prnewswire.com
2025-10-06 19:10:00SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma.
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
globenewswire.com
2025-10-06 12:00:00NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers.
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
globenewswire.com
2025-10-05 23:28:00Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
globenewswire.com
2025-10-05 13:59:00NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors
globenewswire.com
2025-10-03 14:22:00LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Jasper Therapeutics, Inc., (“Jasper” or the "Company") (NASDAQ: JSPR) investors of a class action on behalf of investors that bought securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). Jasper investors have until November 18, 2025 to file a lead plaintiff motion.
DEADLINE ALERT for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
globenewswire.com
2025-10-03 13:14:00BENSALEM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
prnewswire.com
2025-10-03 11:25:00Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
prnewswire.com
2025-10-03 10:00:00NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
2025-10-02 17:15:00LOS ANGELES , Oct. 2, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR)have opportunity to lead the securities fraud class action lawsuit.
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-10-02 14:47:00NEW YORK , Oct. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
globenewswire.com
2025-10-01 14:55:00NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
2025-10-01 12:00:00BENSALEM, Pa. , Oct. 1, 2025 /PRNewswire/ -- The Law Offices of Howard G.